240 related articles for article (PubMed ID: 16898003)
1. [Clinical benefit of S-1 in metastatic breast cancer].
Saeki T
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():202-6. PubMed ID: 16898003
[TBL] [Abstract][Full Text] [Related]
2. [New oral anticancer drug, TS-1 (S-1)--from bench to clinic].
Shirasaka T; Tsukuda M; Inuyama Y; Taguchi T
Gan To Kagaku Ryoho; 2001 Jun; 28(6):855-64. PubMed ID: 11432358
[TBL] [Abstract][Full Text] [Related]
3. [A late phase II clinical study of S-1 in patients with progressed, refractory breast cancer].
Saeki T; Takashima S; Sano M; Horikoshi N; Miura S; Shimizu S; Morimoto K; Kimura M; Taguchi T
Gan To Kagaku Ryoho; 2004 Apr; 31(4):539-47. PubMed ID: 15114697
[TBL] [Abstract][Full Text] [Related]
4. Clinical efficacy of S-1 in pretreated metastatic breast cancer patients.
Shien T; Shimizu C; Akashi-Tanaka S; Yonemori K; Kohno T; Hojo T; Ando M; Katsumata N; Kinoshita T; Fujiwara Y
Jpn J Clin Oncol; 2008 Mar; 38(3):172-5. PubMed ID: 18296424
[TBL] [Abstract][Full Text] [Related]
5. Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies.
Chu QS; Hammond LA; Schwartz G; Ochoa L; Rha SY; Denis L; Molpus K; Roedig B; Letrent SP; Damle B; DeCillis AP; Rowinsky EK
Clin Cancer Res; 2004 Aug; 10(15):4913-21. PubMed ID: 15297391
[TBL] [Abstract][Full Text] [Related]
6. [An early phase II clinical study of S-1 in patients with breast cancer. S-1 Cooperative Study Group (Breast Cancer Working Group)].
Taguchi T; Morimoto K; Horikoshi N; Takashima S; Toge T; Kimura M; Sano M; Aoyama H; Ota J; Noguchi S
Gan To Kagaku Ryoho; 1998 Jun; 25(7):1035-43. PubMed ID: 9644319
[TBL] [Abstract][Full Text] [Related]
7. [Early phase II study of S-1 in patients with advanced head and neck cancer. S-1 Cooperative Study Group (Head and Neck Working Group)].
Inuyama Y; Kida A; Tsukuda M; Kohno N; Satake B
Gan To Kagaku Ryoho; 1998 Jul; 25(8):1151-8. PubMed ID: 9679577
[TBL] [Abstract][Full Text] [Related]
8. [Two cases of advanced pancreatic cancer with cervical lymph node or liver metastasis responding well to S-1 monotherapy].
Funakoshi A; Senju T; Sumii T
Gan To Kagaku Ryoho; 2006 Oct; 33(10):1505-9. PubMed ID: 17033248
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of S-1 monotherapy in paclitaxel- and cisplatin-refractory gastric cancer.
Lee SJ; Cho SH; Yoon JY; Hwang JE; Bae WK; Shim HJ; Chung IJ
Cancer Chemother Pharmacol; 2009 Dec; 65(1):159-66. PubMed ID: 19479256
[TBL] [Abstract][Full Text] [Related]
10. [Invention of a tumor-selective 5-fluorouracil derivative named S-1 by biochemical modulation of 5-fluorouracil].
Shirasaka T; Shimamoto Y; Kato T; Fukushima M
Gan To Kagaku Ryoho; 1998 Feb; 25(3):371-84. PubMed ID: 9492831
[TBL] [Abstract][Full Text] [Related]
11. [Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer].
Yumine K; Kawahara M
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():189-92. PubMed ID: 16898000
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of S-1, a novel oral fluorophyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study Group.
Ohtsu A; Baba H; Sakata Y; Mitachi Y; Horikoshi N; Sugimachi K; Taguchi T
Br J Cancer; 2000 Jul; 83(2):141-5. PubMed ID: 10901361
[TBL] [Abstract][Full Text] [Related]
13. Phase I and pharmacokinetic study of once daily oral administration of S-1 in patients with advanced cancer.
Cohen SJ; Leichman CG; Yeslow G; Beard M; Proefrock A; Roedig B; Damle B; Letrent SP; DeCillis AP; Meropol NJ
Clin Cancer Res; 2002 Jul; 8(7):2116-22. PubMed ID: 12114411
[TBL] [Abstract][Full Text] [Related]
14. [Late phase II study of S-1 in patients with advanced head and neck cancer].
Inuyama Y; Kida A; Tsukuda M; Kohno N; Satake B;
Gan To Kagaku Ryoho; 2001 Oct; 28(10):1381-90. PubMed ID: 11681245
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug.
Hirata K; Horikoshi N; Aiba K; Okazaki M; Denno R; Sasaki K; Nakano Y; Ishizuka H; Yamada Y; Uno S; Taguchi T; Shirasaka T
Clin Cancer Res; 1999 Aug; 5(8):2000-5. PubMed ID: 10473078
[TBL] [Abstract][Full Text] [Related]
16. Phase I study with pharmacokinetics of S-1 on an oral daily schedule for 28 days in patients with solid tumors.
Hoff PM; Saad ED; Ajani JA; Lassere Y; Wenske C; Medgyesy D; Dwivedy S; Russo M; Pazdur R
Clin Cancer Res; 2003 Jan; 9(1):134-42. PubMed ID: 12538461
[TBL] [Abstract][Full Text] [Related]
17. Rapid development of S-1 in the west for therapy of advanced gastric carcinoma.
Ajani JA
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():117-20. PubMed ID: 16897985
[TBL] [Abstract][Full Text] [Related]
18. [Conceptual changes in cancer chemotherapy--biochemical modulation of 5-FU].
Shirasaka T; Yamamitsu S; Tsuji A; Terashima M; Hirata K
Gan To Kagaku Ryoho; 2000 Jun; 27(6):832-45. PubMed ID: 10897209
[TBL] [Abstract][Full Text] [Related]
19. A phase I study of combination therapy of the oral fluorinated pyrimidine compound S-1 with low-dose cisplatin twice-a-week administration (JFMC27-9902 Step2) in patients with advanced gastric cancer using a continual reassessment method.
Morita S; Nakata B; Tsuji A; Mitachi Y; Shirasaka T; Saji S; Ohashi Y; Sakamoto J; Hirakawa K
Jpn J Clin Oncol; 2007 Dec; 37(12):924-9. PubMed ID: 18211983
[TBL] [Abstract][Full Text] [Related]
20. Alternate-day oral therapy with TS-1 for advanced gastric cancer.
Arai W; Hosoya Y; Hyodo M; Yokoyama T; Hirashima Y; Yasuda Y; Nagai H; Shirasaka T
Int J Clin Oncol; 2004 Jun; 9(3):143-8. PubMed ID: 15221596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
